araag2/HINT huggingface dataset:
Clinical trial NCT00636922 (phase 1, status: unknown status)
Conditions: acute myeloid leukemia
ICD codes: C92.A1, C92.A2, C92.61, C92.62, C92.A0, C92.60
Drugs: rad001(everolimus)
SMILES: [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC
Eligibility criteria:

        Untreated AML patients (defined by WHO 2008 criteria) over the age of 60 or
        relapsed/refractory AML over the age of 18 who have received up to 2 previous lines of
        intensive chemotherapy

          -  No prior failure to achieve at least a PR with Azacitidine or Everolimus

          -  Provision of written informed consent

          -  Secondary AML (including therapy-related) are included

          -  Life expectancy of greater than 3 months in relation to diseases other then AML/MDS

          -  ECOG performance status 0 - 3

          -  Electrolyte levels (potassium, calcium (albumin-adjusted), magnesium, phosphorous)
             within normal limits (WNL) or easily correctable with supplements

          -  Adequate hepatic function as defined by bilirubin ≤ 1.5 x the upper limit of normal
             (ULN) and aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x
             ULN

          -  Adequate renal function, with serum creatinine ≤ 1.5 x ULN or GFR > 30 ml/minute

          -  Patients with no uncontrolled active infection

          -  Hydroxyurea ceased 48 hours prior to study therapy

        Exclusion Criteria

          -  Any serious medical or psychiatric conditions which the investigator feels may
             interfere with the patient's ability to give informed consent or participate in the
             procedures or evaluations of the study

          -  History of major non-compliance to medication

          -  Evidence of CNS leukemia

          -  Uncontrolled viral infection with known HIV or Hepatitis type B or C

          -  Currently active gastrointestinal disease (e.g., ulcerative diseases, uncontrolled
             nausea, vomiting, diarrhoea, malabsorption syndrome, or small bowel resection), or
             other disease, that prevents the patient from absorbing or taking oral medication

          -  Any other concurrent severe and/or uncontrolled medical conditions (eg. acute or
             chronic liver disease, infection, pulmonary disease) that in the opinion of the
             investigator could potentiate unacceptable safety risks or jeopardize compliance with
             the protocol

          -  Males with a female partner of childbearing potential do not agree to use at least 2
             effective contraceptive methods throughout the study and for 6 months following the
             date of last dose
Clinical trial NCT01748578 (phase 1, status: completed)
Conditions: dry eye
ICD codes: H04.121, H04.122, H04.123, H04.129, H35.3111, H35.3112, H35.3121
Drugs: ebi-005-1, ebi-005-1 placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Healthy adult males and/or females between the ages of 18 and 65 years

          -  Medically healthy

          -  Best correction vision of greater than or equal to 20/40 in each eye

          -  Non-tobacco/nicotine-containing product users for a minimum of 6 months prior to
             dosing

          -  Tolerate topical administration to eye

          -  Signed and dated, Institutional Review Board (IRB) approved informed consent form
             (ICF) prior to any protocol-specific screening procedures

        Exclusion Criteria:

          -  History or presence of significant cardiovascular, pulmonary, hepatic, renal,
             hematological, gastrointestinal, endocrine, immunologic, dermatologic (including
             sensitive skin on the face), neurological, or psychiatric disease, or any other
             clinically significant disease not deemed acceptable by the PI

          -  History of any primary malignancy, with the exception of basal cell or squamous cell
             carcinomas of the skin or cervical carcinoma in situ or other malignancies curatively
             treated and with no evidence of disease for at least 5 years

          -  Occurrence of active seasonal allergies including ocular allergies (e.g.; annual hay
             fever)

          -  Abnormalities following ophthalmological examination: abnormality of the cornea,
             evidence of ocular inflammation (dry eyes, blepharitis, allergic conjunctivitis,
             iritis, and uveitis), glaucoma, and optic neuropathy

          -  Subjects with a history of laser refractive surgery (laser assisted stromal in-situ
             keratomileusis [LASIK], photorefractive keratectomy [PRK]), radial keratotomy (RK),
             corneal transplantation, dry eyes, or radiotherapy to the eyes

          -  Use of contact lenses currently or within the past one year

          -  Positive urine drug/alcohol or cotinine testing
Clinical trial NCT00389051 (phase 1, status: completed)
Conditions: non-hodgkin's lymphoma
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: bendamustine hydrochloride
SMILES: CN1C(CCCC(O)=O)=NC2=CC(=CC=C12)N(CCCl)CCCl
Eligibility criteria:

        Inclusion Criteria:

        Indolent B cell Non-Hodgkin's lymphoma patients with prior therapy who satisfy the
        conditions listed below. No restrictions regarding gender.

          -  Patients with histologically or cytologically confirmed indolent B cell Non-Hodgkin's
             lymphoma.

          -  Patients who had not received treatment (chemotherapy, antibody therapy and radiation/
             radiotherapy) for more than 4 weeks following prior therapy and who are judged to
             carry no effect from the prior therapy.

          -  Patients aged from 20 to less than 75 years.

          -  Patients who had agreed in-patient during first course therapy.

          -  Patients from whom written consent to participate in this study has been obtained.

        Exclusion Criteria:Patients who meet any of the following criteria will be excluded.

          -  Patients with apparent infections.

          -  Patients with serious complications (hepatic failure or renal failure).

          -  Patients with complication or history of serious heart failure (e.g. cardiac
             infarction, ischemic heart disease).

          -  Patients with serious digestive symptoms (nausea/ vomiting/ diarrhea).

          -  Patients who are known to be positive for HBV, HCV or HIC.

          -  Patients receiving other investigational drugs within 3 months before registration in
             the study.

          -  Patients with allogenic transplant.

          -  Women who are pregnant, of childbearing potential, or lactating.

          -  Patients who do not agree to contraception.

          -  Otherwise, patients who are judged by the investigator as being unsuitable for
             inclusion in the study.
Clinical trial NCT00431015 (phase 1/phase 2, status: completed)
Conditions: lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: ipi-504
SMILES: CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(O)=CC(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)=C2O
Eligibility criteria:

        Inclusion Criteria:

          -  Pathologically confirmed diagnosis of a Stage IIIb (with malignant pleural or
             pericardial effusion) or Stage IV NSCLC

          -  Measurable disease by RECIST criteria.

        Exclusion Criteria:

          -  Treatment for NSCLC with any approved or investigational product within 2 weeks of the
             start of IPI-504 treatment for any small molecule therapy; within 4 weeks of the start
             of IPI-504 treatment for any biologic or any conventional chemotherapy.

          -  Inadequate hematologic or renal or hepatic function

          -  Previous treatment with 17-AAG, DMAG or other known Hsp90 inhibitor.
Clinical trial NCT00279773 (phase 1, status: terminated)
Conditions: acute myeloid leukemia
ICD codes: C92.A1, C92.A2, C92.61, C92.62, C92.A0, C92.60
Drugs: tki258
SMILES: CN1CCN(CC1)C1=CC=C2N=C(NC2=C1)C1=C(N)C2=C(NC1=O)C=CC=C2F
Reason stopped: 
    study was stopped due to time dependent drug accumulation
  
Eligibility criteria:

        Inclusion Criteria:

          -  Confirmed diagnosis of Acute Myeloid Leukemia

          -  Eighteen years of age or older

          -  Life expectancy of at least 2 months

        Exclusion Criteria:

          -  Intracranial disease or epidural disease

          -  Clinically significant cardiac disease

          -  Diabetes mellitus uncontrolled with medication

          -  Pregnant or breast feeding women

          -  Dementia or altered mental status

          -  Known pre-existing clinically significant or uncontrolled disorder of the
             hypothalamic-pituitary axis, adrenal or thyroid glands

          -  Previous pericarditis

          -  Malabsorption syndrome or uncontrolled gastrointestinal symptoms such as
             nausea,diarrhea,vomiting
Clinical trial NCT01491217 (phase 1/phase 2, status: unknown status)
Conditions: advanced metastatic gastric cancer, recurrent gastric cancer
ICD codes: G47.13, J01.41, K11.22, K12.0, N96, F33.8, G03.2
Drugs: paclitaxel
SMILES: [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC
Eligibility criteria:

        Inclusion Criteria:

          1. Patients must histologically or cytologically be diagnosed to have an advanced solid
             cancer. (phaseI)

          2. Advanced/metastatic/recurred gastric cancer(PhaseII)

          3. ECOG performance status ≤ 2

          4. Patients have proper bone marrow, kidney, liver function and patients do not have
             remarkable dysfunction of heart and lung: WBC≥4000/mm3; Platelet ≥100,000/mm3;
             Hemoglobin≥9.0g/dL; ANC≥ 1,500 /mm3; Creatinine ≤ 1.5mg/dL; AST/ALT/ALP ≤ 3 X the
             upper limit of normal; Total bilirubin ≤2.0mg/dL *AST/ALT/ALP ≤ 3 X the upper limit of
             normal but <5 if liver or bone metastasis is present

        Exclusion Criteria:

          1. Patients with blood tumor (ex, leukemia), uncontrolled infectious disease, neurologic
             disorders, metastasis to CNS or ileus (patients requiring non-oral administration of
             anti-biotics to treat active bacterial infection are nor eligible, but patients can
             participate in the trial after complete eradication or control of the infection)

          2. Patients who have received bone marrow transplant or are to receive bone marrow
             transplant.

          3. Patients who had the medical history of atrial or ventricular arrhythmia or congestive
             heart failure or received medical treatment for myocardial infarction within 6 months.
Clinical trial NCT00719173 (phase 1, status: completed)
Conditions: breast cancer, nausea and vomiting
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60, R11.10, R11.12, R11.14, R11.11, K91.0, O21.2, O21.8
Drugs: aprepitant, cyclophosphamide
SMILES: [H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, ClCCN(CCCl)P1(=O)NCCCO1
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Diagnosis of breast cancer

          -  Planning to receive cyclophosphamide 600 mg/m²-1,000 mg/m² IV infusion

               -  No cyclophosphamide dose change between courses 1 and 2

        PATIENT CHARACTERISTICS:

          -  Life expectancy ≥ 2 months

          -  ANC ≥ 1,500/μL

          -  Platelet count ≥ 100 x 10^9/L

          -  Hemoglobin ≥ 9.0 g/dL

          -  Serum creatinine ≤ 1.5 mg/dL

          -  AST/ALT ≤ 2 times upper limit of normal

          -  Not pregnant or nursing

          -  No contraindication to aprepitant

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  No concurrent medications that are CYP3A4 substrates, inhibitors, and/or inducers,
             with the exception of the dexamethasone contained as part of the standard antiemetic
             regimen
Clinical trial NCT00281255 (phase 1/phase 2, status: withdrawn)
Conditions: cardiovascular diseases, cardiomyopathy, dilated, heart diseases, heart failure, congestive
ICD codes: A52.00, A52.09, A50.54, Z01.810, Q87.418, Z13.6, R94.30, I11.0, I11.9, I27.1, I51.9, I09.9, I27.9, I01.8, I50.20, I50.21, I50.22, I50.30, I50.31, I50.32, I50.40
Drugs: allopurinol, dobutamine
SMILES: O=C1N=CN=C2NNC=C12, NC[C@H](O)C1=CC(O)=C(O)C=C1
Reason stopped: 
    infeasible
  
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of idiopathic cardiomyopathy (defined by an ejection fraction less than or
             equal to 35% that has been assessed by any method within 6 months prior to study entry
             AND no evidence of coronary artery disease, as determined by coronary angiography or
             stress perfusion imaging within 2 years prior to study entry)

          -  New York Heart Association (NYHA) Class I - II heart failure

          -  Stable heart failure medication for at least 1 month prior to study entry

          -  Able to lie flat for 45 minutes

        Exclusion Criteria:

          -  History of poorly controlled hypertension and concentric left ventricular hypertrophy
             on echocardiography suggesting hypertensive cardiomyopathy

          -  History of biopsy-proven myocarditis

          -  Peripartum cardiomyopathy

          -  Allopurinol therapy within the 6 months prior to study entry

          -  Allopurinol allergy

          -  Contraindication to allopurinol because of concomitant therapy with one of the
             following: azathioprine, cyclophosphamide, dicumarol, uricosuric agents (e.g.,
             probenecid), ampicillin, amoxicillin, chlorpropamide, or cyclosporine

          -  Acute gout

          -  Estimated creatinine clearance less than 20 ml/min

          -  Total bilirubin greater than 2 times upper limit of normal

          -  Serum aspartate AST or alanine ALT greater than 3 times the upper limit of normal

          -  White blood cell count less than 2,000

          -  Platelet count less than 80,000

          -  Hemoglobin less than 8 mg/dl

          -  Use of intravenous inotropes

          -  History of untreated symptomatic ventricular tachycardia

          -  History of sustained ventricular tachycardia induced by dobutamine

          -  Contraindication to MRI because of one of the following:

               1. Starr-Edwards pre-6000 series prosthetic valves or prosthetic valves for which
                  model can not be determined

               2. Implanted pacemaker

               3. Implanted cardioverter-defibrillator intracranial aneurysm clips

               4. Other implanted medical devices that are known to be MRI incompatible (e.g.,
                  cochlear implants and spinal stimulators)

               5. History of foundry-work that could create ocular metallic fragments

          -  Hospitalization at least 1 month prior to study entry
Clinical trial NCT01155713 (phase 1, status: completed)
Conditions: neoplasm, cancer, tumors
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, E88.3, R97.8, C49.A0, C49.A1, C49.A2, C49.A5, C49.A3
Drugs: tki258
SMILES: CN1CCN(CC1)C1=CC=C2N=C(NC2=C1)C1=C(N)C2=C(NC1=O)C=CC=C2F
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with an advanced solid tumor which has progressed despite standard therapy,
             or for which no standard therapy exists

          -  World Health Organization (WHO) performance status ≤ 2

          -  Patient must meet protocol-specified laboratory values

        Exclusion Criteria:

          -  Patients with brain cancer

          -  Patients who have concurrent severe and/or uncontrolled medical conditions which could
             compromise participation in the study

          -  Patients who have not recovered from previous anti-cancer therapies

          -  Female patients who are pregnant, breast feeding, or not willing to use an effective
             method of birth control

        Other protocol-defined inclusion/exclusion criteria may apply
Clinical trial NCT00556023 (phase 1, status: completed)
Conditions: pancreatic cancer
ICD codes: C25.3
Drugs: cp-675,206 and gemcitabine
SMILES: NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with metastatic pancreatic cancer

          -  Patient must have adequate bone marrow, liver and kidney function

          -  Patient must have an Eastern Cooperative Oncology Group (ECOG) performance score of 0
             or 1

          -  Chemotherapy naive

          -  Inoperable pancreatic cancer

        Exclusion Criteria:

          -  Patient must not have received prior systemic therapy for pancreatic cancer

          -  Patient must not have previously received anti-CTLA4 therapy

          -  History of chronic inflammatory or autoimmune disease
Clinical trial NCT01723735 (phase 1, status: completed)
Conditions: hypercholesterolemia
ICD codes: E78.01, E78.00, Z83.42
Drugs: alirocumab, ezetimibe, ezetimibe placebo, fenofibrate
SMILES: CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1, CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1, CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C1=CC=C(Cl)C=C1
Eligibility criteria:

        Inclusion criteria :

          -  Healthy male /or female subjects,

          -  aged 18 to 65 years old,

          -  with LDL-C > 130 mg/dL

          -  not receiving lipid lowering therapy.

        Exclusion criteria:

          -  Healthy subjects with history or presence of clinically relevant illness.

          -  Subjects currently taking statins, ezetimibe or fenofibrate.

          -  The above information is not intended to contain all considerations relevant to a
             patient's potential participation in a clinical trial.
Clinical trial NCT00115635 (phase 1/phase 2, status: completed)
Conditions: prostate cancer
ICD codes: C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, Z12.5
Drugs: docetaxel, gemcitabine
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically verified adenocarcinoma of the prostate.

          -  Hormone refractory prostate cancer (HRPC) defined as progression during previous
             anti-hormone treatment. Patients must have been off previous anti-androgen therapy for
             more than 4 weeks.

          -  Stage IV disease (verified by imaging or clinical examination).

          -  PSA > 10 microgram/l.

          -  PSA progression defined as a > 25% increase between two independent measurements
             performed with a 1-month interval or more after discontinuation of anti-androgen
             treatment.

          -  Castrate level of testosterone (< 50 ng).

          -  No previous oestrogen or steroid as metastatic prostate cancer treatment.

          -  Satisfactory hepatic function in the form of total bilirubin ≤ UNL (upper normal
             limit), ASAT/ALAT ≤ 2.5 x UNL, alkaline phosphatase ≤ 5 x UNL.

          -  Satisfactory renal function, defined as serum creatinine ≤ 1.5 x UNL.

          -  Satisfactory haematologic function defined as ANC >1.5 x 10^9/l, leucocytes >3.0 x
             10^9/l, thrombocytes ≥ 100 x 10^9/l, haemoglobin > 7 mmol/l

          -  ECOG performance status ≤ 2.

          -  Life expectancy > 3 months.

          -  Patient must be able to adhere to protocol requirements.

          -  Written informed consent.

          -  > 18 years of age.

        Exclusion Criteria:

          -  Previous prostate cancer treatment with oestrogens or steroid hormones.

          -  Previous chemotherapy.

          -  Previous treatment with systemic radioactive isotopes.

          -  Bisphosphonate treatment (concomitant).

          -  Radiation therapy covering more than 25% of the bone marrow producing area.

          -  Other serious coincidental and/or concomitant medical condition.

          -  Symptomatic cerebral metastases.

          -  Other previous or current malignant disease, excluding *adequately treated and cured
             planocellular skin carcinoma; or *other cancer assessed to carry minimal risk of
             recurrence.

          -  ECOG performance status > 2.
Clinical trial NCT01038674 (phase 1, status: completed)
Conditions: inflammation, rheumatoid arthritis
ICD codes: H01.9, H30.93, H05.00, H30.003, H30.013, H30.033, H30.103, M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: anti-il-20, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Informed consent obtained before any trial-related activities

          -  A diagnosis of rheumatoid arthritis made at least 3 months prior to screening

          -  Active rheumatoid arthritis, characterised by a DAS28 equal or above 3.2

          -  Methotrexate treatment (stable dose, equal or below 25 mg/week) for at least 4 weeks
             prior to study start (subjects receiving stable doses of oral corticosteroids, and/or
             non-steroidal anti-inflammatory drugs and/or acetaminophen and/or opioids according to
             prescribed recommended doses can be included)

          -  Male subjects and female subjects of non-child bearing potential

        Exclusion Criteria:

          -  Body mass index (BMI) less than 18.5 or above 35.0 kg/m2

          -  Subjects with chronic inflammatory autoimmune disease other than rheumatoid arthritis

          -  History of or current inflammatory joint disease other than rheumatoid arthritis

          -  Chronic or ongoing infectious disease requiring systemic anti-infectious treatment
             within 2 weeks prior to study start

          -  Past or current malignancy (as judged by the investigator)

          -  Clinically significant cardiac or cardiovascular disease

          -  Positive for human immunodeficiency virus (HIV), hepatitis or tuberculosis

          -  Blood donation or blood loss of more than 0.45L within 2 months prior to study start,
             or longer if required by local regulations

          -  Breast-feeding women